retatrutide type 2 diabetes ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide 10 mg — Sequentia

Here is an official image and detailed information about Jascayd (nerandomilast), the recently approved drug for idiopathic pulmonary fibrosis (IPF): FDA Approval News: FDA Approves Jascayd Manufacturer Site: Jascayd by Boehringer Ingelheim #Pharmacy #DrugUpdate #IdiopathicPulmonaryFibrosis #FDAApproval #Jascayd #LungHealth #PharmaceuticalSciences #HealthcareInnovation To view or add a comment, sign in Explore related topics Explore content categories

Gastrointestinal upset occurs in 5-10% of users and typically develops within 30-60 minutes of taking the medication on an empty stomach

Drinking more water and eating fibre-rich foods can help a lot

PMC Alharbi SH, et al